Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy

X
Trial Profile

An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Octreotide
  • Indications Pancreatic cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms RADIANT-1
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2010 Results from this study and the other two RADIANT trials will form the basis for regulatory filings in late 2010 according to a Novartis media release.
    • 24 Jun 2009 Final results presented at the 11th World Congress on Gastrointestinal Cancer.
    • 17 Sep 2008 Added Novartis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top